Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 7;2(2):CD001215.
doi: 10.1002/14651858.CD001215.pub2.

WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma

Tom Crosby  1 , Reg Fish, Bernadette Coles, Malcolm Mason
Affiliations

WITHDRAWN: Systemic treatments for metastatic cutaneous melanoma

Tom Crosby et al. Cochrane Database Syst Rev. .

Abstract

Background: Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and the therapeutic aim remains one of palliation.Many agents are used alone or in combination with varying degrees of toxicity and cost. It is unclear whether evidence exists to support these complex regimens over best supportive care / placebo.

Objectives: To review the benefits from the use of systemic therapies in metastatic cutaneous melanoma compared to best supportive care/placebo, and to establish whether a 'standard' therapy exists which is superior to other treatments.

Search methods: Randomised controlled trials were identified from the MEDLINE, EMBASE and CCTR/CENTRAL databases. References, conference proceedings, and Science Citation Index/Scisearch were also used to locate trials. Cancer registries and trialists were also contacted.

Selection criteria: Randomised controlled trials of adults with histologically proven metastatic cutaneous melanoma in which systemic anti-cancer therapy was compared with placebo or supportive care.

Data collection and analysis: Study selection was performed by two independent reviewers. Data extraction forms were used for studies which appeared to meet the selection criteria and, where appropriate, full text articles were retrieved and reviewed independently.

Main results: No randomised controlled trials were found comparing a systemic therapy with placebo or best supportive care in metastatic cutaneous melanoma.

Authors' conclusions: There is no evidence from randomised controlled clinical trials to show superiority of systemic therapy over best supportive care / placebo in the treatment of malignant cutaneous melanoma.Given that patients with metastatic melanoma frequently receive systemic therapy, it is our pragmatic view that a future systematic review could compare any systemic treatment, or combination of treatments, to single agent dacarbazine.

PubMed Disclaimer

Conflict of interest statement

None.

Update of

References

    1. Atzpodien J, Kirchner H, Franzke A, Wandert T, Probst M, Buer J, Duensing S, Ganser A. Results of a randomised clinical trial comparing SC interleukin‐2, SC alpha‐2a‐interferon, and IV bolus 5‐fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients. Proceedings of the American Association for Clinical Oncology 1997;16:326.
    1. Bajetta E, Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa‐2a in the treatment of advanced melanoma. Journal of Clinical Oncology 1994;12(4):806‐11. - PubMed
    1. Balch CM, Houghton AN, Peters LJ. Cutaneous Melanoma. In: Devita VT Jr, Hellman S, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. Fourth. Philadelphia: J.B. Lippincott Co, 1993:1612‐61.
    1. Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ. Randomized prospective trial of DTIC (NSC‐45388) alone versus BCNU (NSC‐409962) plus vincristine (NSC‐67574) in the treatment of metastatic malignant melanoma. Cancer Treatment Reports 1976;60(5):595‐600. - PubMed
    1. Burke PJ, McCarthy WH, Milton GW. Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 1971;27(3):744‐50. - PubMed

Publication types

Substances

LinkOut - more resources